Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:31:20 13/06/2025 BST			5-day change	1st Jan Change
269.70 ^CHF	-1.06%		+0.56%	+5.56%

11:39pm	Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	RE
06-11	US FDA approves Nuvation Bio's rare lung cancer drug	RE

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

Published on 24/04/2024 at 16:27, updated on 24/04/2024 at 16:50

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Roche Holding AG

Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	11:39pm	RE
US FDA approves Nuvation Bio's rare lung cancer drug	06-11	RE
Roche Canada Says Health Canada Authorizes PiaSky	06-11	RE
EQT, Sanofi Co-Led $135 Million Funding Round for Spanish Biotech Company SpliceBio	06-11	DJ
EQT leads financing round in SpliceBio	06-11	FW
Pharma Mar's Supplemental New Drug Application for Lung Cancer Drug Combo Gets US FDA Priority Review	06-10	MT
Roche's Middle Eastern Arm Launches Sustainable Healthcare Lab Certification Initiative	06-10	MT
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients	06-06	RE
ROCHE HOLDINGS AG : Jefferies is Neutral	06-05	ZD
ROCHE HOLDINGS AG : Deutsche Bank remains a Sell rating	06-05	ZD
Formycon receives market approval in Brazil for Lucentis biosimilar	06-05	DP
Swiss Market Index Extends Rally; Roche Gains on EU Win	06-04	MT
Roche's Evrysdi Tablet Gets EU Clearance for Spinal Muscular Atrophy Treatment	06-04	MT
Roche: EU approves Evrysdi tablet for SMA	06-04	CF
EU Approves New Tablet Formulation for Roche's Spinal Muscular Atrophy Treatment	06-04	MT
EU Approves Roche's Evrysdi Tablet For Spinal Muscular Atrophy	06-04	MT
Roche's Evrysdi Tablet Approved By European Commission	06-04	RE
Healthcare Stocks Rise Tuesday -- Healthcare Roundup	06-03	DJ
Swiss Stocks Up as Inflation Turns Negative, OECD Slashes Estimates	06-03	MT
Health insurers in favor of cost containment for drug spending	06-03	DP
Pharmamar Announces Positive Results from the Phase 3Imforte Study of Zepzelca®? (Lurbinectedin) in Combination with Atezolizumab	06-03	CI
Roche: positive results in lung cancer	06-03	CF
Roche's Tecentriq With Lurbinectedin Increases Survival to Small-Cell Lung Cancer, Study Says	06-03	DJ
Roche Reports Positive Results from Tecentriq-based Combination Treatment for Small Cell Lung Cancer	06-03	MT
Roche: Tecentriq Combined With Lurbinectedin Shows Survival Benefit In Extensive-Stage Small Cell Lung Cancer	06-03	RE

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,249

Sector

Pharmaceuticals

Calendar

06-16 - Kepler Cheuvreux Virtual CEO CFO Conference

More about the company